To our knowledge, there is no prospective study identifying the link between the recently approved triple VEGFR Inhibitor, tivozanib and AngII/ET-1/Oxidative stress/NO in the induction of hypertension and renal cardiovascular damage. This evidence concerns the gene AGT and hypertensive disorder.